Literature DB >> 8097126

Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties.

H J Möller1.   

Abstract

The development and evaluation of the use of neuroleptics for negative symptoms of schizophrenia is becoming more and more of interest. However, severe methodological problems can lead to wrong conclusions in this field. The differentiation between primary and secondary negative symptoms and the interrelationship between negative symptoms, depression and akinesia have to be carefully considered. Many studies in this field are not conclusive because of such methodological pitfalls. After a careful review of published studies in this field no final conclusions can be drawn as to whether neuroleptics in general are effective in primary minus symptoms or whether certain neuroleptics are superior to others. Negative symptoms accompanying productive symptoms do improve with the neuroleptic treatment of the productive symptoms.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097126     DOI: 10.1016/0924-977x(93)90289-x

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  9 in total

Review 1.  Review: treatment of schizophrenia. State of the art.

Authors:  H J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

2.  Statistical differentiation between direct and indirect effects of neuroleptics on negative symptoms.

Authors:  H J Möller; H Müller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

Review 3.  Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.

Authors:  B Fulton; K L Goa
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

4.  A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study.

Authors:  H J Möller; H Müller; R L Borison; N R Schooler; G Chouinard
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

Review 5.  Management of the negative symptoms of schizophrenia: new treatment options.

Authors:  Hans-Jürgen Möller
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 6.  Adverse effects of antipsychotic agents. Do newer agents offer advantages?

Authors:  D G Owens
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

Review 7.  Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia.

Authors:  H J Möller; H M van Praag; B Aufdembrinke; P Bailey; T R Barnes; J Beck; H Bentsen; F X Eich; L Farrow; W W Fleischhacker
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

Review 8.  Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes.

Authors:  Danielle Coppola; Leo J Russo; Robert F Kwarta; Ruana Varughese; Juergen Schmider
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

9.  Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia.

Authors:  Ibrahim Turkoz; Cynthia A Bossie; Bryan Dirks; Carla M Canuso
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.